Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model

62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [18F]Fluorodeoxyglucose and L-Methyl-[11C]Methionine PET

“…24 In accordance with these findings, a hypoxic imaging study by use of [ 18 F]fluoromisonidazole revealed a positive relationship but not a precisely matched uptake to that of FDG in gliomas, 11 which seems to be similar to the results of our present study. These findings imply that the positive relationship between FDG-PET and hypoxic-PET may indicate increased glycolysis, glucose uptake, and hypoxia in GBM.…”

Pathophysiologic Correlation Between 62Cu-ATSM and 18F-FDG in Lung Cancer

“…Differences in pathologic features that characterize the expansive growth pattern of SCC and clustering of microgrowth at each alveolar structure in adenocarcinoma may have resulted in the different accumulation patterns of PET tracers. The intratumoral distribution of 62 Cu-ATSM and 18 F-FDG was assessed previously in several animal studies with a wide variety of solid tumors implanted in mice and rabbits (29)(30)(31)(32). Heterogeneity of tumor hypoxia and glucose metabolism was found in most of these tumor models with outer accumulation of 62 Cu-ATSM, compared with inner accumulation of 18 F-FDG in the tumor, irrespective of their sizes.…”

Positron emission tomography to assess hypoxia and perfusion in lung cancer

“…The short-lived radionuclides can be used for sequential measurements, whereas radionuclides with longer half lives do Table 2 for full names. Lewis et al [133] , Yuan et al [134] , Kersemans et al [135] , Matsumoto et al [136] Ballegeer et al [137] , Bowen et al [138] , Lewis et al [133] , Myerson et al [139] , O'Donoghue et al [72] Ballegeer et al [137] , Hansen et al [140] , Matsumoto et al [136] , McCall et al [66] , O'Donoghue et al [72] , Oh et al [74] , Yuan et al [134] Grigsby et al [141] , Tateishi et al [142] , Valtorta et al [143] , Weeks et al [144] Dence et al [145] , Kersemans et al [135] , Lewis et al [146] , Matsumoto et al [136] , O'Donoghue et al [72] Dehdashti et al [86] , Lohith et al [67] , Wong et al [80] , Zhang et al [81] Chao et al [147] , Dehdashti et al [148] , Dehdashti et al [149] , Dietz et al [150] , Grassi et al [151] , Grigsby et al [141] , Kositwattanarerk et al [152] , Laforest et al [153] , Lewis et al [154] , Minagawa et al [155] , Nyflot et al [156] [ Mahy et al [158] , Mahy et al …”

“…This tracer shows favorable kinetics with rapid uptake in hypoxic tissue and fast clearance from normoxic tissues, enabling imaging within 30 min after injection [66,67] . However, the exact uptake mechanism of [Cu]ATSM is still under debate [63,68,69] and several preclinical studies have shown that [Cu]ATSM uptake depends on tumor type and other characteristics than hypoxia alone [70][71][72][73][74][75][76] .…”